Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Genzyme

Status and phase: Completed; Phase 2

Conditions: Thyroid Cancer

Treatments: Drug: ZD6474 (vandetanib)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00098345

D4200C00008

LPS14954 (Other Identifier)

Details and patient eligibility

About

The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.

Enrollment: 40 patients

Sex: All

Ages: 18 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Locally advanced or hereditary medullary thyroid cancer
• Signed informed consent
• One or more measurable lesions

Exclusion criteria

• Brain metastases or spinal cord compression
• Specific laboratory ranges
• Specific heart problems
• Prior chemotherapy and/or radiation therapy
• Participation in other trials within 30 days

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Caprelsa (vandetanib) 300 mg

Experimental group

Description:

Daily oral dose of Caprelsa (vandetanib) 300mg

Treatment:

Drug: ZD6474 (vandetanib)